Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 821 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 821 shares of the stock in a transaction on Monday, October 26th. The stock was sold at an average price of $20.00, for a total value of $16,420.00. Following the sale, the insider owned 54,513 shares in the company, valued at approximately $1,090,260. This represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total value of $13,446.25.
• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total value of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total value of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $101,798.97.

Beta Bionics Stock Performance

Shares of BBNX opened at $17.85 on Thursday. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The stock’s 50-day simple moving average is $19.21 and its 200 day simple moving average is $14.90. The stock has a market capitalization of $803.07 million, a price-to-earnings ratio of -10.82 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The business had revenue of $35.51 million during the quarter. On average, research analysts forecast that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on BBNX. Robert W. Baird increased their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Wells Fargo & Company initiated coverage on shares of Beta Bionics in a research report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 price target for the company. The Goldman Sachs Group boosted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. William Blair started coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating on the stock. Finally, Barclays initiated coverage on Beta Bionics in a research report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average target price of $23.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC lifted its position in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after purchasing an additional 240,000 shares during the last quarter. BlackRock Inc. purchased a new position in Beta Bionics in the 2nd quarter worth approximately $52,340,000. Bank of New York Mellon Corp purchased a new position in Beta Bionics in the 2nd quarter worth approximately $1,926,000. Squarepoint Ops LLC purchased a new position in Beta Bionics in the 2nd quarter worth approximately $2,524,000. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the 1st quarter worth $5,518,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results modestly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the consensus loss estimate of $0.53. Revenue reached $35.51 million, above the approximately $34.7 million analyst estimate. The company also updated its full-year 2026 guidance, although the details were not provided in the available reports. Beta Bionics Announces Third Quarter 2026 Financial Results
• Neutral Sentiment: Insider sale was limited in size. Director Mark Hopman sold 821 shares at an average price of $20, reducing his position by about 1.48%. While insider selling can weigh on sentiment, the transaction represented a relatively small portion of his holdings. SEC Insider Filing
• Negative Sentiment: Multiple law firms publicized a pending securities class action. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026, with a November 3, 2026 deadline to seek lead-plaintiff status. The repeated notices increase legal and reputational concerns, although the allegations have not been proven.
• Negative Sentiment: The allegations center on iLet safety and regulatory disclosures. Legal notices allege Beta Bionics failed to disclose material information, including a June 2025 FDA Form 483 and more than 18,000 unreported iLet-related complaints. The firms contend that subsequent disclosures concerning FDA compliance and device safety were followed by a sharp stock decline. Any litigation costs, regulatory action, or additional product issues could further pressure the shares. Beta Bionics Securities Fraud Class Action Notice

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.